Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzastaurin + R-CHOP in DGM1+ High-Risk DLBCL
NCT03263026Phase 3Completed
- Sponsor
- Denovo Biopharma
- Start
- Mar 2018
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in diffuse large B-cell lymphoma (DLBCL) comparing R-CHOP + Enzastaurin with R-CHOP + Placebo (2 arms). Primary endpoint: Overall Survival in Subjects Who Possess the DGM1™ Biomarker at 12 months. Started Mar 2018; status: completed.
02
Drugs
enzastaurin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03263026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03263026.